Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID07142304

IMPACT: Clinical Investigation of Advanced Compression Technology to Improve Chemotherapy-Induced Peripheral Neuropathy - Safety and Efficacy Study

Led by Luminate Medical, Inc. · Updated on 2026-04-02

142

Participants Needed

15

Research Sites

26 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Chemotherapy drugs used to treat cancer can cause a side effect called chemotherapy-induced peripheral neuropathy (CIPN), which affects the nerves in the hands and feet. Researchers are evaluating the Lilac Glove and Boot devices that apply gentle pressure to the hands and feet to reduce chemotherapy reaching peripheral nerves. This study aims to assess whether these devices can help prevent moderate to severe nerve symptoms during chemotherapy treatment for patients with solid tumors. Participants will be randomly assigned to receive either the Lilac Device, which must be worn continuously during chemotherapy infusion and for up to two hours afterward, or a sham device that looks similar but applies less pressure. The devices are fitted and activated by healthcare professionals before chemotherapy starts. The study includes adults receiving specific chemotherapy regimens based on Oxaliplatin or Paclitaxel, with or without targeted therapies. During the study, participants will wear the devices during chemotherapy infusions and complete questionnaires about nerve symptoms. Researchers will monitor for nerve symptoms at 12 weeks after starting treatment, focusing on overall symptoms and those affecting the hands. The study will track safety, device use, and symptom progression, with participation lasting through the chemotherapy period and follow-up. All study visits and questionnaires will help determine the device's impact on nerve health during chemotherapy.

CONDITIONS

Brief Title

The Lilac Device Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older with diagnosed solid tumor cancer
  • Planned intravenous chemotherapy with at least 4 cycles and no planned surgery pause
  • Receiving specific chemotherapy regimens based on Oxaliplatin or Paclitaxel
  • Concurrent use of targeted agents or immunotherapy allowed
  • Hands and feet size within study device range
  • Plan to complete taxane- or platinum-based chemotherapy within 12 months
  • ECOG performance status between 0 and 2
  • Willing and able to sign informed consent
  • Willing to wear the Lilac devices during and after infusion as prescribed
  • Able to complete study questionnaires in available languages
Not Eligible

You will not qualify if you...

  • Existing peripheral neuropathy (grade > 0)
  • Neurotoxic chemotherapy treatment within the past 1 year
  • Positive pregnancy test for those with childbearing potential
  • Known allergy to device materials including natural rubber latex
  • Open wounds, sores, or injuries on hands, arms, feet, or legs where device is applied
  • Significant peripheral arterial ischemia
  • Untreated or uncontrolled hypertension
  • Poorly controlled diabetes
  • Weight above 140 kg at enrollment
  • History or suspicion of hand or foot metastasis
  • Use of other investigational devices or compression therapies for neuropathy
  • Current use of neuropathy medications like Pregabalin or Gabapentin
  • Cognitive, psychiatric, or mobility issues preventing study compliance
  • Participation in other clinical trials that may cause neuropathy within 30 days
  • Previous participation in this study at an earlier stage

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Implementation

Duration - Up to 12 months, corresponding to the chemotherapy treatment duration

Participants receive the Lilac Device or a sham device worn during chemotherapy infusion to reduce the risk of peripheral neuropathy. Devices are fitted and turned on before infusion begins, worn continuously during infusion, and for up to two hours afterward.

Visits occur with each chemotherapy infusion over multiple cycles

Follow-up

Duration - 12 weeks post-treatment

Participants are monitored for peripheral neuropathy symptoms for 12 weeks after completing treatment with the device and chemotherapy.

Follow-up visits up to 12 weeks after treatment completion

Trial Site Locations

Total: 15 locations

1

Palomar Health (Topography)

Poway, California, United States, 92064

Withdrawn

2

Eastern Connecticut Hematology Oncology

Norwich, Connecticut, United States, 06360

Actively Recruiting

3

Hialeah Hospital

Hialeah, Florida, United States, 33013

Actively Recruiting

4

Hawaii Cancer Care

Honolulu, Hawaii, United States, 96813

Actively Recruiting

5

Hope and Healing Cancer Services

Hinsdale, Illinois, United States, 60521

Actively Recruiting

6

Parkview Cancer Institute

Fort Wayne, Indiana, United States, 46845

Actively Recruiting

7

Health Partners Frauenshuh Cancer Center

Minneapolis, Minnesota, United States, 55426

Actively Recruiting

8

Fairview Masonic Cancer Clinic, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

9

Astera Cancer Care

East Brunswick, New Jersey, United States, 08816

Actively Recruiting

10

New York Cancer and Blood Specialists

New York, New York, United States, 11967

Actively Recruiting

11

Springfield Regional Cancer Center

Springfield, Ohio, United States, 45502

Actively Recruiting

12

Mercy Health St. Elizabeth Hospital

Youngstown, Ohio, United States, 44512

Actively Recruiting

13

Vanderbilt-Ingram Cancer Center

Nashville, Tennessee, United States, 37232

Actively Recruiting

14

Hospital Sisters Health System - St.Vincent & St.Mary's

Green Bay, Wisconsin, United States, 54301

Actively Recruiting

15

St. James Hospital

Dublin, Dublin, Ireland

Actively Recruiting

Loading map...

Research Team

L

Lalita K Kota, M.S.

B

Barbara Oliveira, Ph.D.

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

Assessment of Effectiveness of Closed-loop Spinal Cord Stimu...

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Actively Recruiting

5 locations

Feasibility Testing of a Virtual Tai Chi Program for Chemoth...

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Actively Recruiting

1 location

Evaluation of Gut Microbiome Profiles in Patients with Chemo...

Chemotherapy Induced Peripheral Neuropathy (CIPN)

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here